SCHEMBL10163488

SCHEMBL10163488

Cn1c(=O)oc2ccc(CNC(=O)c3cc(C(=O)NCc4ccccc4)n4ncc(F)c4n3)cc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 2/20 0.44
ADAMTS4 O75173 1/20 0.44
MMP3 P08254 1/20 0.44
TP53 P04637 3/20 0.42
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 3/20 0.41
HPGD P15428 3/20 0.41
LMNA P02545 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GAA P10253 1/20 0.41
RAB9A P51151 1/20 0.41
MKNK1 Q9BUB5 1/20 0.41
MAPT P10636 2/20 0.40
USP2 O75604 1/20 0.40
TSHR P16473 1/20 0.40
POLB P06746 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
EGFR P00533 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8225565 0.94 TP53 (0.43) MMP13ADAMTS4MMP3TP53LMNA
SCHEMBL14450006 0.94 MMP13 (0.44) MMP13ADAMTS4MMP3TP53MAPT
SCHEMBL8225568 0.94 MMP13 (0.43) MMP13ADAMTS4MMP3TP53POLB
SCHEMBL10163453 0.93 L3MBTL1 (0.45) MMP13ADAMTS4MMP3TP53ALDH1A1
SCHEMBL10163511 0.93 TP53 (0.46) MMP13ADAMTS4MMP3TP53ALDH1A1
SCHEMBL10163455 0.93 POLB (0.45) MMP13ADAMTS4MMP3TP53ALDH1A1
SCHEMBL8226281 0.93 MMP13 (0.42) MMP13ADAMTS4MMP3TP53ALDH1A1
SCHEMBL8221168 0.92 MMP13 (0.43) MMP13ADAMTS4MMP3ALDH1A1KDM4E
SCHEMBL10163495 0.92 MMP13 (0.41) MMP13ADAMTS4MMP3TP53LMNA
SCHEMBL8226363 0.92 MMP13 (0.41) MMP13ADAMTS4MMP3TP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.